Microbiota alterations in patients treated for susceptible or drug-resistant TB
BACKGROUND: We investigated alterations of human microbiota under anti-TB therapies in relationship to the level of Mycobacterium tuberculosis drug response. METHODS: Stool, sputum, and oral swab samples were analysed from participants with treatment-naïve TB and participants treated for drug-suscep...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-08-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000008/art00005 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591355978711040 |
|---|---|
| author | M. Hauptmann B. Kalsdorf J.E. Akoh-Arrey C. Lange U.E. Schaible |
| author_facet | M. Hauptmann B. Kalsdorf J.E. Akoh-Arrey C. Lange U.E. Schaible |
| author_sort | M. Hauptmann |
| collection | DOAJ |
| description | BACKGROUND: We investigated alterations of human microbiota under anti-TB therapies in relationship to the level of Mycobacterium tuberculosis drug response. METHODS: Stool, sputum, and oral swab samples were analysed from participants with treatment-naïve TB and participants treated for drug-susceptible TB (DS-TB), drug-resistant TB without injectable drugs (DR-TB-inj–), or with injectable drugs (DR-TB-inj+) at 27–42 days of therapy. RESULTS: From September 2018 to December 2019, 5 participants with treatment-naïve TB, 6 participants with DS-TB, 10 participants with DR-TB-inj–, and 4 participants with DR-TB-inj+ were recruited. Reduced alpha diversities in stool samples indicated more profound dysbiosis in participants treated for DR-TB than in participants treated for DS-TB (–12% (non-significant) for DS-TB, –44% (P < 0.001) for DR-TB-inj–, and –60% (P < 0.05) for DR-TB-inj+ compared to treatment-naïve participants). While reduced abundances were observed in numerous taxa, genus Lactobacillus revealed the most substantial abundance increase in sputa of participants treated for DR-TB compared to treatment-naïve ones (P < 0.05 for DR-TB-inj– and DR-TB-inj+). Notably, a group of nosocomial pneumonia-associated taxa was increased in oral swabs of the DR-TB-inj+ compared to the treatment-naïve group (P < 0.05). CONCLUSIONS: Second-line anti-TB therapy in participants with DR-TB results in altered microbiota, including reduced alpha diversity and expansion of phylogenetically diverse taxa, including pathobionts. |
| format | Article |
| id | doaj-art-21dcc6be33bf4f948695d49629d1d9b9 |
| institution | Kabale University |
| issn | 3005-7590 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | International Union Against Tuberculosis and Lung Disease (The Union) |
| record_format | Article |
| series | IJTLD Open |
| spelling | doaj-art-21dcc6be33bf4f948695d49629d1d9b92025-01-22T12:14:14ZengInternational Union Against Tuberculosis and Lung Disease (The Union)IJTLD Open3005-75902024-08-011835536110.5588/ijtldopen.24.03255Microbiota alterations in patients treated for susceptible or drug-resistant TBM. Hauptmann0B. Kalsdorf1J.E. Akoh-Arrey2C. Lange3U.E. Schaible4Priority Area Infections, Division of Cellular Microbiology,Outpatient Pulmonology Ward, andPriority Area Infections, Division of Cellular Microbiology,Division of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.Priority Area Infections, Division of Cellular Microbiology,BACKGROUND: We investigated alterations of human microbiota under anti-TB therapies in relationship to the level of Mycobacterium tuberculosis drug response. METHODS: Stool, sputum, and oral swab samples were analysed from participants with treatment-naïve TB and participants treated for drug-susceptible TB (DS-TB), drug-resistant TB without injectable drugs (DR-TB-inj–), or with injectable drugs (DR-TB-inj+) at 27–42 days of therapy. RESULTS: From September 2018 to December 2019, 5 participants with treatment-naïve TB, 6 participants with DS-TB, 10 participants with DR-TB-inj–, and 4 participants with DR-TB-inj+ were recruited. Reduced alpha diversities in stool samples indicated more profound dysbiosis in participants treated for DR-TB than in participants treated for DS-TB (–12% (non-significant) for DS-TB, –44% (P < 0.001) for DR-TB-inj–, and –60% (P < 0.05) for DR-TB-inj+ compared to treatment-naïve participants). While reduced abundances were observed in numerous taxa, genus Lactobacillus revealed the most substantial abundance increase in sputa of participants treated for DR-TB compared to treatment-naïve ones (P < 0.05 for DR-TB-inj– and DR-TB-inj+). Notably, a group of nosocomial pneumonia-associated taxa was increased in oral swabs of the DR-TB-inj+ compared to the treatment-naïve group (P < 0.05). CONCLUSIONS: Second-line anti-TB therapy in participants with DR-TB results in altered microbiota, including reduced alpha diversity and expansion of phylogenetically diverse taxa, including pathobionts.https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000008/art00005mycobacteriumnosocomial pneumonia |
| spellingShingle | M. Hauptmann B. Kalsdorf J.E. Akoh-Arrey C. Lange U.E. Schaible Microbiota alterations in patients treated for susceptible or drug-resistant TB IJTLD Open mycobacterium nosocomial pneumonia |
| title | Microbiota alterations in patients treated for susceptible or drug-resistant TB |
| title_full | Microbiota alterations in patients treated for susceptible or drug-resistant TB |
| title_fullStr | Microbiota alterations in patients treated for susceptible or drug-resistant TB |
| title_full_unstemmed | Microbiota alterations in patients treated for susceptible or drug-resistant TB |
| title_short | Microbiota alterations in patients treated for susceptible or drug-resistant TB |
| title_sort | microbiota alterations in patients treated for susceptible or drug resistant tb |
| topic | mycobacterium nosocomial pneumonia |
| url | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000008/art00005 |
| work_keys_str_mv | AT mhauptmann microbiotaalterationsinpatientstreatedforsusceptibleordrugresistanttb AT bkalsdorf microbiotaalterationsinpatientstreatedforsusceptibleordrugresistanttb AT jeakoharrey microbiotaalterationsinpatientstreatedforsusceptibleordrugresistanttb AT clange microbiotaalterationsinpatientstreatedforsusceptibleordrugresistanttb AT ueschaible microbiotaalterationsinpatientstreatedforsusceptibleordrugresistanttb |